作者: H. T. Meryman , M. Mincheff
DOI: 10.1007/978-1-4615-3094-7_2
关键词: Platelet transfusion 、 Azathioprine 、 Incidence (epidemiology) 、 Blood transfusion 、 Clinical Practice 、 Immune tolerance 、 Kidney 、 Medicine 、 Internal medicine 、 Extensive data
摘要: As early as 1946, Medawar [1] reported delayed rejection of skin homografts in rabbits following donor-specific blood transfusions, an observation subsequently confirmed animals by a number other investigators [2–6]. The impact these reports on clinical practice was negligible since the data were collected mainly rodents and it well known that transfusions could also immunize patients thereby jeopardize success or even opportunity for subsequent transplant [7]. However, 1973, Opelz et al [8] published indicating allogeneic pre-transplant significantly reduced incidence episodes renal transplants humans improved 1-year kidney survival rates. This report followed more extensive [9] confirmations which have been summarized at least three major review articles [10–12]. Alloimmunization continued to be hazard but introduction immuno-suppressive agents, particularly azathioprine [13, 14], greatly this threat both become standard component therapy.